Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 6/20 | 1.00 |
| ▸ | G6PD | P11413 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 4/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 2/20 | 0.70 |
| ▸ | GABRD | O14764 | 2/20 | 0.70 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.70 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.70 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.70 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.70 |
| ▸ | GABRE | P78334 | 2/20 | 0.70 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfaxalone SCHEMBL644125 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL643098 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614070 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24766358 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614107 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24675016 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614053 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24765814 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614074 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL9809348 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355157-A1 | NEUROACTIVE STEROIDS AND METHODS OF PREPARATION | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2021-11-18 | — | — | US | claimed |
| EP-1458399-B1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2012-08-08 | — | — | EP | claimed |
| US-7960367-B2 | Pregnane steroids and their use in the treatment of CNS disorders | UMECRINE AB (SE) | 2011-06-14 | — | — | US | claimed |
| EP-2275109-A2 | Pregnane steroids for use in the treatment of CNS disorders | Umecrine AB (SE) | 2011-01-19 | — | — | EP | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| WO-2007025064-A2 | METHODS OF USING SELECTIVE llβ-HSD INHIBITORS TO TREAT GLUOCORTICOID ASSOCIATED STATES | THE MIRIAM HOSPITAL (US) | 2007-03-01 | — | — | WO | claimed |
| US-20050222099-A1 | Pregnane steroids for use in the treatment of cns disorders | UMECRINE AB (SE) | 2005-10-06 | — | — | US | claimed |
| EP-1458399-A1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | Umecrine AB (SE) | 2004-09-22 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2003059357-A1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2003-07-24 | — | — | WO | claimed |
| EP-0659072-B1 | PHARMACEUTICAL EMULSIONS CONTAINING BIOACTIVE STEROIDS | PHARMACIA AB (SE) | 2001-11-07 | — | — | EP | claimed |
| US-6083941-A | TREATMENT OF NEUROPATHIC PAIN, DRUG WITHDRAWAL/DEPENDENCY, EPILEPSY, GLAUCOMA, CHRONIC NEURODEGENERATIVE DISEASES, AMYOTROPHIC LATERAL SCLEROSIS, ANXIETY DISORDERS, BRAIN CELL DEATH, ISCHAEMIA, STROKE, TRAUMA | TRUSTEES OF BOSTON UNIVERSITY (US) | 2000-07-04 | — | — | US | claimed |
| US-5869068-A | AGONIST SUBSTANCE OF ONE OR A NUMBER OF RECEPTORS ASSOCIATED WITH A CHLORINE CHANNEL ARE USEFUL FOR SLACKENING AND/OR RELAXING CUTANEOUS TISSUE, AND IN PARTICULAR FOR THE PURPOSE OF TREATING WRINKLES AND FINE LINES OF THE SKIN. | L'OREAL (FR) | 1999-02-09 | — | — | US | claimed |
| WO-1993017711-A1 | NEW CYCLODEXTRINS AND NEW FORMULATED DRUGS | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1993-09-16 | — | — | WO | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | PURETECH LYT, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-4192871-A | ANAESTHETICS - STEROIDS | GLAXO LABORATORIES LIMITED (GB) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | GABRA1 3686/4885GABRB2 3280/4885G6PD 3960/4885 |
| US-20210355157-A1 | NEUROACTIVE STEROIDS AND METHODS OF PREPARATION | GAP43, CHRNB4, ADRA2C | GABRA1 63/4885GABRB2 100/4885G6PD 3145/4885 |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | CYP21A2, CYP46A1, CYP17A1 | GABRA1 2097/4885GABRB2 2004/4885G6PD 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.